List of Jublia drug patents
Jublia is owned by Bausch.
Jublia contains Efinaconazole.
Jublia has a total of 16 drug patents out of which 0 drug patents have expired.
Jublia was authorised for market use on 06 June, 2014.
Jublia is available in solution;topical dosage forms.
Jublia can be used as topical treatment of tinea unguium by using an applicator for applying a solution for treating tinea unguium to an affected part of a patient, topical treatment of onychomycosis of the toenail(s) due to trichophyton rubrum and trichophyton mentagrophytes, antimycotic uses, specifically treatment of onychomycosis; topical treatment of the toenail(s) due to trichophyton rubrum and trichophyton mentagrophytes, antimycotic uses, specifically treatment of onychomycosis.
The generics of Jublia are possible to be released after 25 April, 2035.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7214506 | BAUSCH | Method for treating onychomycosis |
Feb, 2026
(3 years from now) | |
| US11213519 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(4 years from now) | |
| US9566272 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(4 years from now) | |
| US9877955 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(4 years from now) | |
| US10512640 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(4 years from now) | |
| US10828369 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(4 years from now) | |
| US9861698 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jul, 2030
(7 years from now) | |
| US8039494 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jul, 2030
(7 years from now) | |
| US10105444 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jul, 2030
(7 years from now) | |
| US9302009 | BAUSCH | Compositions and methods for treating diseases of the nail |
Oct, 2030
(7 years from now) | |
| US8486978 | BAUSCH | Compositions and methods for treating diseases of the nail |
Oct, 2030
(7 years from now) | |
| US10864274 | BAUSCH | Stabilized efinaconazole formulations |
Oct, 2034
(11 years from now) | |
| US9662394 | BAUSCH | Stabilized efinaconazole compositions |
Oct, 2034
(11 years from now) | |
| US10342875 | BAUSCH | Stabilized efinaconazole compositions |
Oct, 2034
(11 years from now) | |
| US10828293 | BAUSCH | Anti-infective methods, compositions, and devices |
Oct, 2034
(11 years from now) | |
| US10478601 | BAUSCH | Applicator |
Apr, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Apr 27, 2023 |
Drugs and Companies using EFINACONAZOLE ingredient
Market Authorisation Date: 06 June, 2014
Treatment: Antimycotic uses, specifically treatment of onychomycosis; Topical treatment of the toenail(s) due to trichophyton rubrum and trichophyton mentagrophytes; Topical treatment of onychomycosis of the toenail(s) due to trichophyton rubrum and trichophyton mentagrophytes; Topical treatment of tinea unguium by using an applicator for applying a solution for treating tinea unguium to an affected part of a patient
Dosage: SOLUTION;TOPICAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic